While typically, you would assume that oncologists would prefer face to face interactions with ThoughtLeaders, our poll demonstrated different results.
When asked, “What is the preferred method of interacting with ThoughtLeaders?” over half of those polled responded via computer.
Remember this statistic the next time you consider flying a ThoughtLeader to a remote location to meet with cancer treaters.
To see how MDOutlook is able to provide you further actionable intelligence, email me at [email protected]
Assumptions have been made for years that nationally recognized ThoughtLeaders are substantially more effective at modifying treatment behavior than regional or local experts, thus commanding a larger honorarium.
However, in MDOutlook’s new Insights & Influence Report on the U.S. market, one section analyzes the impact that national, regional, and local ThoughtLeaders, as well as peer groups, have on influencing oncologists’ treatment behavior. This report has been developed in partnership with Medallion Healthcare.
The results show, while national U.S. ThoughtLeaders do have more overall influence, the gap between the national experts and the regional experts is found to be much smaller than anticipated.
MDOutlook’s Insights & Influence Report is a comprehensive survey of oncologists which measures the impact of various intelligence strategies employed and how large of an impact those strategies have on influencing oncologists’ treatment behaviors. If you are interested in purchasing the full report, click here.
At MDOutlook, we can leverage our proprietary database of over 12,000 validated oncology ThoughtLeaders and panel of 110,000+ cancer treaters globally to assist you. Click here to learn more.
How has the 58th ASH Annual Meeting been received by the oncology community? How much does attendance at this (or other major meetings) impact the uptake of the new clinical information? MDOutlook’s® innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 58th ASH Annual Meeting in San Diego will help you understand these questions, in addition to the specific clinical topics covered by our research.
Building on over 40 analyses covering ASH, ASCO, SABCS, ESMO and ESH for nearly a decade, this is our second report from the 2016 ASH meeting. We are proud to support the entire cancer community with this research.
This OncoPoll™ report focuses on the development of CAR-T Cell therapies for a variety of hematologic malignancies. It examines a number of target antigen + malignancy therapies in development plus some additional thoughts meaning on their impact in oncologist’s practice today – although none are yet commercially available.
Our analyses of the meeting impact on US oncologists (study sample n=100, see graphic) this year compares the different impact of the conference on those who attended the conference versus those who learned about the news from other sources as well treatment setting.
US oncologists are relatively aware of and see the development of CAR-T Cell therapies as very important to the B-lineage malignancies for which they are currently being studied. The leading CAR-T Cell approach, CD19-targeted in B-Cell acute lymphocytic leukemia, slightly leads the pack in both awareness and expected importance
Even though CAR-T Cell therapies are not yet commercially available, oncologists are up-to-date about them in their routine practices:
Referral of patients to the clinical trials is common, overall averaging about 4 per respondent over the past year
Oncologists, especially ASH attendees, frequently are being asked about these approaches by their patients, even outside of the clinical trial setting
The involvement of NIH in the development of CAR-T Cell therapies is seen as a positive for US oncologists
Attendance at the meeting is not necessary for this new information to impact clinical practices. While initial awareness of the information may be lower, upon learning about it, the physicians who did not attend recognize the clinical importance to a similar extent as those who did attend
MDOutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review.
To discuss your oncology and disease intelligence needs, please contact us at [email protected] or +1.404.496.4136.
MDOutlook® proudly continues our innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 58th ASH Annual Meeting in San Diego. Supporting the entire cancer community and building on over 40 analyses covering ASH since 2008, this is our first report from the 2016 meeting.
This OncoPoll™ focuses on B-cell lymphomas. It covers the choice between Rituxan® and Gazyva® in the front line setting for different lymphomas and the use of Rituxan and Revlimid® in the maintenance setting.
Our analyses of the meeting impact on US oncologists this year ((study sample n=100, see graphic) compares the different impact of the conference on those who attended the conference versus those who learned about the news from other sources:
• Oncologists see the comparison of the anti-CD20 antibodies Rituxan and Gazyva, in combination with chemotherapy in the front line setting for follicular and diffuse large B-cell lymphomas, as important clinical developments
• Overall usage of Gazyva in the front-line setting is expected to rise at the expense of Rituxan
• Use of maintenance strategies, with Rituxan in mantle cell lymphoma and Revlimid in CLL, is expected to continue to rise in popularity for hematologic malignancies
• Attendance at the meeting is not necessary for this new information to impact clinical practices. While initial awareness of the information may be lower, upon learning about it, the physicians who did not attend are just as, if not more likely to change their practices to integrate the clinical improvements
MDOutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community.
To discuss your oncology and disease intelligence needs, please contact us at [email protected] or +1.404.496.4136.
Join other oncology science professionals in benefiting from MDOutlook’s ThoughtLeader Intelligence platform for more informed, quicker decision-making. Gain access to over 115,000 oncologists, cancer treaters and identified, ranked and profiled ThoughtLeaders. Explore the oncology treater landscape in all cancers for every important market.
For a quick, 90-sec tour, check out our new video.
For more information or to schedule a demo of our oncology intelligence portal, contact us at [email protected] or +1.404.496.4136.
Invariably you will need to ask physician experts for their advice. Ad Boards have traditionally offered important lines of communication between the life science industry and healthcare providers.
And, those times call for the experts to organize. MDOutlook knows how to pull the right ThoughtLeaders into a room to give you the physicians with the most relevant experience for your needs.
MDOutlook’s ability to identify the right ThoughtLeaders and overcome challenging logistics are demonstrated in the following case study.
Customer
MDOutlook’s ability to identify the right ThoughtLeaders and overcome challenging logistics are demonstrated in the following case study.
Challenge
Client wished to identify investigators and establish a clinical development network in Asia, related to a new compound in Hepato-Cellular Carcinoma (HCC).
Approach
MDOutlook tasked with identification, recruitment logistics and moderation for Investigator meeting in Taiwan
Panel Composition: 8 ThoughtLeader Experts from Japan, Taiwan and South Korea
Turnaround time was short (within 5 weeks)
Unique Proposition MDOutlook
Immediate access to pre-qualified and profiled international database of Oncologists
Institutional knowledge of HCC, allowing for articulate conversation with the ThoughtLeaders
Organizational aptitude to arrange an Ad Board in Asia, including simultaneous translation of 3 languages; easily navigating cultural considerations
Results
Seamless meeting logistics and professional moderation
Extremely efficient identification process and fast recruitment of investigators who met specific Client requirements
Value Delivered
Deep knowledge and insight gained on clinical development and trial setup in Asia
Client Feedback
“It led us to a targeted clinical development program in Asia and clinical investigator relationships. It led to a much more sophisticated understanding of the landscape market in Asia, which is very important segment,” – feedback from CEO.
To learn more about this case, to discuss your oncology intelligence needs, or to schedule a demo of our oncology intelligence portal, contact us at [email protected] or +1.404.496.4136.
Developing a list of relevant ThoughtLeaders in a new therapeutic area is a foundational task for any team. But, then what and how? On what do you base their importance for your brand? How do you determine their influence in the community? And do you identify those hard-to-find ThoughtLeaders outside the Top 30?
MDOutlook has a different approach.
We give you a roadmap to know who, why, how and when to approach the right ThoughtLeaders, by profiling their interests and network. In this case study, we show you how to take the guesswork out of identifying these valuable doctors.
Customer
International pharmaceutical company, building up their oncology portfolio, especially in women’s health.
Challenge
Client wished to develop a list of top ThoughtLeaders and in-depth profiles to engage them strategically and tactically (Strategic Advisory Group, Speakers, Investigators).
Approach
Peer-nomination survey US and EU
Extensive desk research
Data-mining of MDOutlook ThoughtLeader Intelligence system
Unique Proposition MDOutlook
Leveraging direct access to pre-qualified panel of multi-disciplinary treaters of ovarian cancer
Real-time system profiling of physicians
Transparency of leadership and influence algorithms, weighting and process
Results
Long list of 300+ ThoughtLeaders based on publications, leadership, clinical trials and peer nominations
Customized top-30 list based on proprietary algorithm and provided extensive profile on each ThoughtLeader (Attribute Dial™)
Value Delivered
4-Week turnkey project delivering roadmap and insight on the most influential ThoughtLeaders in their product’s therapeutic area. Leading to more meaningful conversations with physicians.
Client Feedback
“This is awesome insight, and especially the ThoughtLeader model allows us to query the data, and fine-tune ranking based on different weighting of criteria. You delivered very robust results that will allow us to engage with the right ThoughtLeaders for the right opportunity using the right drivers. All four speakers at a recent symposium were identified through MDOutlook and engaged as result of this project,” expressed the Therapy Area Leader, Medical Affairs.
Launching a product in a new disease area requires a steep learning curve – for every member of the team. With MDOutlook’s unmatched global panel of cancer treaters, we can streamline that process for those in the field and in management. This case study demonstrates how access to our unique intelligence portal improves the efficiency of those in the field.
Customer
International biotech, building up its oncology product portfolio.
Challenge
Client desired to have a targeting and pre-call profiling system to drive commercial engagement of ThoughtLeaders and physicians. Client had successfully used MDOutlook previously at different company in niche HemOnc space.
Approach
Intelligence Portal Access provided to 100+ company staff, ranging from field commercialization to brand management and executives
Training and User Guide provided as part of annual subscription
Integration with existing CRM system (Veeva)
Ongoing user support provided by MDOutlook team
Unique Proposition MDOutlook
Access robust US panel of CML treaters
Standalone portal that is updated real-time with licensed data feeds
Continued ranking analysis based on new data
Seamless integration with existing CRM system; monthly updates of changed records
Integrated customer target list with profiles
Results
Real-time profiling of key account targets
Supplemented with disease intelligence and ThoughtLeader profiling and prioritization analytics
ThoughtLeader network mapping provides alternate avenues to approach targets
Value Delivered
Out-of-box and integrated solution supporting on-going commercialization processes
Easy integration and seamless experience for users
Pre-call planning, targeting and overall knowledge of the CML space has much improved. Leading to more meaningful conversations with physicians
Client Feedback
“MDOutlook is a valuable tool for many departments in our organization. The type of information provided helps guide decision making from both the internal as well as customer facing teams,” according to the U.S. Marketing Director.
To learn more about this case, to discuss your oncology intelligence needs, or to schedule a demo of our oncology intelligence portal, contact us at [email protected] or +1.404.496.4136.
Shaping your brand strategy is likely on your mind 24/7, and almost 365 days in the year. A recent case study from MDOutlook reviews how a focused approach to disease intelligence critically defines a roadmap for strategic brand decisions moving forward.
Customer
Global pharmaceutical company, currently with therapeutics in Hepato-Cellular Carcinoma (HCC).
Challenge
Client required a comprehensive overview of the patient pathways for patients diagnosed with metastatic disease in this evolving therapeutic area. Input for strategic planning and to address specific market access challenges.
Approach
Project spanned 5 major European markets
An in-depth literature review was combined with qualitative ThoughtLeader interviews and a quantitative online survey of over 250 HCC treaters in Europe
Interim and final reporting
Unique Proposition MDOutlook
Robust panel of pre-qualified and profiled treaters of HCC allowed for the required penetration in each country
High level strategic perspective and disease knowledge went into development of discussion guides and surveys to allow for a broad review of the marketplace
System integration of panel, survey technology and data capture allows for timely accrual
Results
Deep insight into the current treatment landscape that involved a comprehensive look at both systemic and localized treatments
Comprehensive patient treatment pathway maps by country and in the aggregate for EU5
Understanding of current treatment patterns, specific to client brand and competitive treatments by disease stage, performance status and treatment setting
Value Delivered
Developed a comprehensive patient treatment pathway showing current treatment patterns in early, intermediate and advanced disease and estimation of likely future trends to guide brand building, market access and future product portfolio decisions.
Client Feedback
This is ground breaking research, as no one has comprehensively mapped out the HCC marketplace in such detail. Having your strategic guidance on what the key learnings are have helped move us forward. The reports are being circulated corporate-wide, as many departments are finding value in this research, including market access and publication planning. We have decided to use the data and results as input for a couple of scientific publications.
To learn more about this case, to discuss your oncology intelligence needs, or to schedule a demo of our oncology intelligence portal, contact us at [email protected] or +1.404.496.4136.
While typically, you would assume that oncologists would prefer face to face interactions with ThoughtLeaders, our poll demonstrated different results.
